Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...

VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Initiating Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI over IBB for higher ...

From broad domestic exposure to global pharma and biotech, these funds cover the healthcare sector's main themes.

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started in January ...

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs?

Investors choosing between Invesco Nasdaq Biotechnology ETF (NASDAQ:IBBQ) and State Street SPDR S&P Pharmaceuticals ETF (NYSEMKT:XPH) could weigh the lower costs and broader diversification of IBBQ ...

Biotechnology investors remain confident in the sector's outlook even after a major comeback this year — and they're picking ...